Shattuck Labs, Inc. Q2 FY2021 earnings call

• Taylor Schreiber highlighted milestones since IPO in Oct 2020, clinical progress of SL-172154 and SL-279252, and submission of clinical data to SITC. - Lini Pandite discussed progress on SL-172154 including enrollment in Phase 1 trials, safety profile, expansion into hematologic malignancies, and progress on SL-279252 with dose escalation plans. - Andrew Neill provided financial update with cash and cash equivalents at $304.8M as of June 30, 2021, and R&D/GA expenses detailed. - Introduction of Abhinav Shukla as Chief Technical Officer.

Shattuck Labs is a clinical-stage biotech focused on ARC platform compounds, but there are no traditional product segments with revenue reported. The focus is on the clinical development of SL-172154 and SL-279252.

• Financial guidance unchanged from IPO in Oct 2020. - Expected cash runway through year-end 2024. - Expansion into AML and MDS trials for SL-172154 included in internal forecasts.

Q: Follow-up on receptor occupancy for CD47 and SL-172154 A: Taylor Schreiber mentioned receptor occupancy levels to be disclosed at SITC, comparing with other CD47 targeted agents.

Q: Key biochemical signals for SL-172154 entering immunologically active dose range and monotherapy activity in heme indications A: Taylor and Lini discussed safety data, pharmacokinetic profile, pharmacodynamic effects, and plans for combo trials in AML and MDS.

Q: Clinical relevance of OX40 stimulation pushing T-cells out of blood and PD-L1 positivity in SL-279252 A: Taylor explained OX40 pharmacodynamic effects and plan to enrich for PD-L1 positive patients in SL-279252 trials.

Q: Immune mediated toxicity and dose escalation for SL-172154 and PD-L1 positivity in SL-279252 A: Lini discussed monitoring for toxicity and plan to select PD-L1 positive patients for SL-279252.

Q: Fc activity of next ARC program and dose escalation gating factors for SL-172154 A: Taylor mentioned no additional disclosure yet on next ARC program and discussed gating factors for Phase 2 dose selection in SL-172154